US · Healthcare · Biotechnology
EPS came in at -1.23 against a street estimate of -2.06 — a beat of 40.3%.
Analysts rate Nektar Therapeutics a strong buy (10 buy, 2 hold, 0 sell out of 12) with an average price target of $133.08.
| Fund | Stake |
|---|---|
| FMR Inc | 14.84% |
| BlackRock Inc | 8.62% |
| Bvf Inc | 7.00% |
| Two Seas Capital LP | 5.74% |
| Vanguard Capital Management, LLC | 4.38% |
| Two Sigma Investments LLC | 3.52% |
| Vestal Point Capital LP | 2.93% |
| Morgan Stanley - Brokerage Accounts | 2.74% |
| Document | Date |
|---|---|
| Reg FD disclosure · Q4 2026 HEADLINE NUMBERS • Nektar Therapeutics filed a Form 8-K dated October 1, 2026. • The filing reports new data from the Phase 2b REZOLVE-AA clinical t | 2026-10-01 |
| Company announcement · Q3 2026 NEKTAR THERAPEUTICS – FORM 8-K SUMMARY HEADLINE NUMBERS • Jury verdict awarded Nektar Therapeutics $90 million in damages against Eli Lilly and Comp | 2026-09-25 |
| Reg FD disclosure · Q3 2026 NEKTAR THERAPEUTICS FORM 8-K SUMMARY HEADLINE NUMBERS • Company: Nektar Therapeutics (Nasdaq: NKTR) • Filing Date: September 8, 2026 • Headquarters: | 2026-09-08 |
| Quarterly report · Q2 2026 NEKTAR THERAPEUTICS - FORM 10-Q SUMMARY Quarter Ended June 30, 2026 --- HEADLINE NUMBERS • Cash and investments: $1,023.4 million as of June 30, 20 | 2026-08-14 |
| Results announced · Q3 2026 NEKTAR THERAPEUTICS – Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Cash and investments: $1,023.4 million as of June 30, 2026, up from $245.8 millio | 2026-08-13 |
| Shareholder vote results · Q2 2026 NEKTAR THERAPEUTICS – FORM 8-K SUMMARY HEADLINE NUMBERS • Annual Stockholder Meeting held June 4, 2026 • Director election: Howard W. Robin elected | 2026-06-05 |
| Quarterly report · Q1 2026 NEKTAR THERAPEUTICS – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash and investments: $731.6 million as of March 31, 2026 ($15.1 million cash + $419.0 | 2026-05-08 |
| Material agreement · Q2 2026 NEKTAR THERAPEUTICS - 8-K SUMMARY HEADLINE NUMBERS • Company established equity distribution agreement for up to $150,000,000 in common stock offeri | 2026-05-08 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Split | 1 : 15 effective Jun 9, 2025 | 2025-06-09 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Nektar Therapeutics — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.